Clinical Trials Browser

Phase 3 × Uterine Cervical Neoplasms × Platinum Compounds × Clear all

NCT04906993 2025-09-09

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Phase 3 Active not recruiting

Uterine Cervical Neoplasms